检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]哈尔滨医科大学实验动物学部,黑龙江哈尔滨150086 [2]黑龙江省北方股骨头坏死专科研究院,黑龙江哈尔滨150006 [3]哈尔滨商业大学,黑龙江哈尔滨150076
出 处:《中成药》2003年第3期220-222,共3页Chinese Traditional Patent Medicine
摘 要:目的 :测定血能达片的急性毒性和验证其抗栓疗效为选药提供依据。方法 :小白鼠一次Ig血能达 2 6g/kg ;五组动物分别给血能达 (XND) 3g/kg ,溶栓胶囊 (RSC) 1 .2 5g/kg,复方丹参 (CDDP) 1 .2 5g/kg,消栓通络 (XSTL) 2 .5g/kg和NSIg ,qd 1次 ,连续 7d。第 7日药后 1h ,IVCollagen Adr诱发血栓 [1 ] ,观察死亡数 ;用毛细血管法测凝血时间 ,扭体法测痛。结果 :小白鼠口服最大耐受量为 2 6g/kg ,临床用量的866 .7倍 ;4种药物除消栓通络外 ,均有明显的抗栓作用 (P <0 .0 5~0 .0 1 ) ;还证实中、高剂量血能达尚有延长凝血时间和镇痛作用 (P <0 .0 5~ 0 .0 1 ) ,其余 3种药则没有。结论 :血能达毒性小 ,具有溶栓胶囊 ,复方丹参等效的抗栓疗效 。Objective: To determine the maximal tolerance of Xunengda Tablets on mice and explore curative effects of its antithrombotic effect and provide the theoretical basis for selecting drugs. Methods:Mice were given maximal dose, 26g·kg -1 of body weight, XND Ig once; Divided 53 mice into five groups, they were administered XND tab.(3g·kg -1 ), RSC(1.25g·kg -1 ), CDDP(1.25g·kg -1 ), XSTL(2.5g·kg -1 ), and NS once daily for 7 days, repectively; 1h after treatment the seventh day, the animals of groups iv. were given collagen adr by producing whole organism thrombus, observing the mortality, They were determined coagulation time with the blood capillaries and the number of writhings per mouse was recorded in order to determine pain. Results:Maximal tolerance (Ig) is 26g·kg -1 , 886.7 times the dose of clinical application apart from XSTL, three kinds of drug showed the avidence of antithrombotic effect ( P < 0.05 ~ 0.01 ); In the study, the middle、maximal dose of XND tab. proved that they could prolong coagulation time and analgesic effects. Conclusion: XND tab. toxicity was small and possessed equivalent antithrombotic effect of RSC and CDDP, also had anticoagulation and analgesic effect.
关 键 词:血能达 Collagen-Adr 扭体反应 最大耐受量
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.147